Introduction

• Gastrointestinal disorders cover a full spectrum of conditions ranging from physiological dysfunction and benign lesions to precancerous lesions and malignant tumors. In vitro diagnostics (IVD) play a core role in early detection, early diagnosis, early stratification and early intervention.
• JOINSTAR's Gastrointestinal Solution focuses on early gastric cancer screening and gastric function assessment. Core markers include Pepsinogen I (PGI), Pepsinogen II (PGII), and Gastrin-17 (G17).

Clinical Applications

• PG I/II and G17 are diagnostic indicators for gastric cancer and gastrointestinal injury. These markers reflect gastric function status, and the "triple combination screening" effectively identifies high-risk populations for gastric cancer.
• Gastroenterology: Gastric mucosa functional assessment and regular follow-up for chronic gastritis and atrophic gastritis.
• Oncology Department: Early screening and risk assessment for high-risk gastric cancer populations.
• Health Check-up Centers: Early screening program for gastrointestinal tumors, suitable for asymptomatic high-risk populations.
• Geriatrics Department: Routine gastric function assessment and health management for elderly patients.